Statistics for Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Total visits
| views | |
|---|---|
| Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial | 138 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| Pembrolizumab As Second-Line Therapy in Patients.pdf | 929 |
Top country views
| views | |
|---|---|
| United States | 42 |
| Chile | 35 |
| Slovenia | 2 |
| Germany | 1 |
| Mexico | 1 |
Top city views
| views | |
|---|---|
| Miami | 37 |
| Santiago | 27 |
| Concepcion | 5 |
| Alameda | 3 |
| San Bernardo | 2 |
| Campbell | 1 |
| Sacramento | 1 |
| Temuco | 1 |
| Zapopan | 1 |